Risk of insulin resistance with statin therapy in individuals without dyslipidemia: A propensity-matched analysis in a registry population
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyun, Myung Han | - |
dc.contributor.author | Jang, Jae Won | - |
dc.contributor.author | Choi, Byoung Geol | - |
dc.contributor.author | Na, Jin Oh | - |
dc.contributor.author | Choi, Cheol Ung | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Kim, Eung Ju | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.contributor.author | Lee, Eunmi | - |
dc.contributor.author | Seo, Hong Seog | - |
dc.date.accessioned | 2021-08-30T22:24:40Z | - |
dc.date.available | 2021-08-30T22:24:40Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 0305-1870 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/55537 | - |
dc.description.abstract | Several studies suggest the higher vulnerability of individuals with lower low-density lipoprotein cholesterol (LDL-C) levels to diabetes mellitus. However, the discordance between high and low baseline LDL-C levels shown by statin-induced insulin resistance is not fully understood. This study aimed to explore the relationship between baseline LDL-C levels and the risk of statin-induced insulin resistance during statin therapy. In total, 2660 (451 with dyslipidemia and 2209 without dyslipidemia) consecutive patients were enrolled. Their baseline clinical data were adjusted using a propensity score matching analysis, using the logistic regression model. Insulin resistance index was based on the homeostatic model assessment-insulin resistance (HOMA-IR) and was monitored for a median of 2 years. Among the individuals who received statin therapy, those with and without dyslipidemia showed significantly decreased LDL-C levels (all P < .0001) and significantly increased fasting plasma insulin levels (Delta = +24.1%, P = .0230; Delta = +30.1%, P < .0001); however, their glycated haemoglobin A1c and fasting blood glucose levels did not change (all P > .05). Although HOMA-IR was positively associated with statin therapy in individuals with and without dyslipidemia, statistically significant difference during follow-ups was observed only in individuals without dyslipidemia (Delta = +15.6%, P = .1609; Delta = 24.0%; P = .0001). Insulin resistance was higher in statin users without baseline dyslipidemia than in those with dyslipidemia. Thus, statin therapy could increase the risk of statin-induced insulin resistance in individuals with normal baseline cholesterol levels. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | METABOLIC SYNDROME | - |
dc.subject | PLASMA-GLUCOSE | - |
dc.subject | CHOLESTEROL | - |
dc.subject | EZETIMIBE | - |
dc.subject | SIMVASTATIN | - |
dc.subject | ATORVASTATIN | - |
dc.subject | PRAVASTATIN | - |
dc.subject | ABSORPTION | - |
dc.subject | FAT | - |
dc.subject | INHIBITION | - |
dc.title | Risk of insulin resistance with statin therapy in individuals without dyslipidemia: A propensity-matched analysis in a registry population | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Na, Jin Oh | - |
dc.contributor.affiliatedAuthor | Choi, Cheol Ung | - |
dc.contributor.affiliatedAuthor | Kim, Jin Won | - |
dc.contributor.affiliatedAuthor | Kim, Eung Ju | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.contributor.affiliatedAuthor | Seo, Hong Seog | - |
dc.identifier.doi | 10.1111/1440-1681.13272 | - |
dc.identifier.scopusid | 2-s2.0-85080096315 | - |
dc.identifier.wosid | 000530851800004 | - |
dc.identifier.bibliographicCitation | CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, v.47, no.6, pp.947 - 954 | - |
dc.relation.isPartOf | CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY | - |
dc.citation.title | CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY | - |
dc.citation.volume | 47 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 947 | - |
dc.citation.endPage | 954 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Physiology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Physiology | - |
dc.subject.keywordPlus | METABOLIC SYNDROME | - |
dc.subject.keywordPlus | PLASMA-GLUCOSE | - |
dc.subject.keywordPlus | CHOLESTEROL | - |
dc.subject.keywordPlus | EZETIMIBE | - |
dc.subject.keywordPlus | SIMVASTATIN | - |
dc.subject.keywordPlus | ATORVASTATIN | - |
dc.subject.keywordPlus | PRAVASTATIN | - |
dc.subject.keywordPlus | ABSORPTION | - |
dc.subject.keywordPlus | FAT | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordAuthor | dyslipidemia | - |
dc.subject.keywordAuthor | insulin resistance | - |
dc.subject.keywordAuthor | statin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.